Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • Impact Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery for Pancreatic Cancer
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • Catalyst Grant Program
        • Catalyst Grant Recipients
          • Evan Abt, PhD
          • Jason Link, PhD
          • Roger Lo, MD, PhD
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • PNET Pathway Grant Program
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Donate Now
    • Give in Tribute →
      • Create a Tribute Page
      • Search for Tribute Fund
    • Ways to Donate →
      • Monthly Giving
      • Donor-Advised Funds
      • Planned Giving
      • Matching Gifts
      • Car Program
    • Fundraise →
      • Purple Ribbon Fundraisers
      • Create a Tribute Page
      • Social Media
      • Fundraising Resources
      • Make Custom Shirts
      • Signature Events
    • Participate →
      • November Awareness Month →
        • World Pancreatic Cancer Day
      • Volunteer
      • Shop Online Store
      • Wedding Program
      • Awareness Resources
      • Signature Events
    • Event Calendar
    • Get Inspired
  • SEARCH
Home / News / Chemotherapy for Pancreatic Cancer Patients: Less is More!

Chemotherapy for Pancreatic Cancer Patients: Less is More!

Our ongoing Patient & Family Webinar Series continues with new information about how the dosing and frequency of chemotherapy may affect patient outcomes

July 10, 2020

Our Patient & Family Webinar series continues with a presentation on chemotherapy for pancreatic cancer patients. Dr. Isacoff will present Chemotherapy for Pancreatic Cancer Patients: Less is More! We are excited to have him share his findings on why lower, more frequent doses of chemotherapy may be a more patient friendly treatment regimen, with fewer side effects and better survival rates.

Dr. William H. Isacoff, who leads the Pancreatic Cancer Center of Los Angeles, has earned a reputation as one of the foremost gastrointestinal oncologists within the United States. He has developed innovative treatments which have significantly extended the lives of pancreatic patients throughout the country. He has worked for decades to form better, safer and more effective treatments for patients battling pancreatic cancer and other gastrointestinal cancers.

With the use of low dose “metronomic” chemotherapy without radiation, Dr. Isacoff and the Pancreatic Surgical Team at UCLA have down staged more than 60 patients who upon initial diagnosis were felt to be inoperable. After successful “metronomic” treatment with a combination of chemotherapies, the patients were then able to become surgical candidates. Seventy-five percent of those patients were found to have lymph nodes that were uninvolved with metastatic disease as a result of the prolonged use of effective chemotherapy. Dr. Isacoff shares these promising results and more information on how lower, more frequent doses of chemotherapy may impact a patient’s outcome.

Watch Webinar

Dr. Isacoff’s Metronomic Manuscript can be seen here »
Learn more about Dr. Isacoff and schedule a phone consultation »

SPONSORS & SUPPORTERS
A very special thanks to our Sponsors & Supporters for helping ensure that these vital patient resources can be offered free-of-charge in place of our Annual Symposium.

California Community Foundation, Caroline Dockrell, Fineberg Foundation, Dr. Robert Richter Foundation Fund, Sidney Stern Memorial Trust, Joanne & Ken Weinman in memory of Sylvia R. Weiner

image_pdfimage_print

Filed Under: News, Patient & Family Webinar

Research Identifies Loss of Protein Linking Chronic Pancreatitis to Pancreatic Cancer, May Present New Tailored Therapy
23 Years of Faithful Support Leads to Results!

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact